With the Cannabis SAFE Banking Act heading to the US Senate, cannabis businesses would be able to to work with financial institutions for their business needs.
The US House of Representatives recently approved the Secure and Fair Enforcement (SAFE) Banking Act of 2021, also known as the SAFE Banking Act (1). This law provides the possibility for financial institutions, such as banks, to conduct business with cannabis enterprises that are licensed in states which allow cannabis for either recreational, medical use, or both (2). The SAFE Banking Acts’ purpose is to remove the fear banks have of being penalized by federal authorities due to the illegality of cannabis at the federal level.
With a 321-101 vote, the House of Representatives passed the bill along to the US Senate where it may be considered for ratification.
The issues surrounding cannabis’ status at the federal level have made banks hesitant to transact business with establishments that are involved in selling cannabis or cannabis-related products. Banks have experienced a reluctance to work with cannabis businesses because of the concern of being found in transgression of federal regulations. The intentions of the SAFE Banking Act are to give clarification on any proceeds that are generated by licensed cannabis firms within states that have cannabis laws should not be looked at as illegal. Instructions are included in the bill for federal regulatory agencies to draft appropriate guidelines so that banking activities could be overseen at a national level.
Due to the limited options to do financial transactions, cannabis industry businesses were forced to run their establishments in cash or use smaller financial institutions such as credit unions. Analysts believe that the lack of collaboration with banks has held back the development of the cannabis industry in jurisdictions where it is legal (2). A considerate amount of banking associations lobbied in support of the legislation because of being placed in difficult positions of listening to state regulators calls for banks to welcome cannabis establishments but also fearing federal regulators that hold cannabis as a highly controlled substance that should not be available for use. Through pushing Congress to take action on the SAFE Banking Act, financial institutions hope to receive a concrete legal position on whether or not they are able to work with state-legal and licensed cannabis companies. Currently in the US, 36 states have structures established to regulate medical cannabis and 17 states have approved the recreational use of cannabis.
The SAFE Banking Act of 2021 will now be entering the US Senate where Majority Leader Chuck Schumer has indicated his support for the cannabis banking bill, along with various other policy reforms with respect to cannabis. Schumer has expressed that the legislative chamber is ready to move forward on cannabis measures regardless of President Biden’s views on the topic, which has been considered “lukewarm” in regard to cannabis reform (3).
Rep. Earl Blumenauer (D-OR), co-chair of the Congressional Cannabis Caucus, said (4) “it’s time for us to address this inconsistency, it’s time for us to pass, again, the SAFE Banking Act and it’s time for us to move forward with legalization on the federal level.” Additionally, he added, “I appreciate us being at this point—a critical first step along the path to full legalization, which I’m confident will happen this Congress, and not a moment too soon.”
On the House floor, Rep. Ed Perlmutter (D-CO) stated (4), “Even if you are opposed to the legalization of cannabis, you should support this bill. American voters have spoken and continue to speak—and the fact is, you can’t put the genie back in the bottle. Prohibition is over.”
If the SAFE Banking Act is ratified into law, cannabis industry enterprises will have to jump over one less hurdle in running their business activities.
Ep 24, Part III: Data Transparency in Cannabis Testing with Yasha Kahn
December 26th 2024In the final part of this episode, Evan Friedmann and Yasha Kahn discuss the need for a national entity to centralize cannabis data collection, moving from snapshot data to continuous updates. They emphasize the importance of accurate lab data and adverse event tracking, suggesting QR codes on packaging to report issues. Yasha suggests harsher consequences for result manipulation and suggests collaboration between state departments and federal entities to support underfunded regulators. They also discuss the potential benefits of off-the-shelf testing and the importance of stability testing. Finally, Yasha shares his top three reading recommendations for the audience.
Ep 24, Part II: Data Transparency in Cannabis Testing with Yasha Kahn
December 12th 2024Evan Friedmann and Yasha Kahn, co-founder of MCR Labs, discuss the discrepancies between current regulations and data on mycotoxins and pesticides in cannabis products. They highlight the need for updated regulations based on new data, emphasizing the importance of accurate testing and labeling. They also discuss the issue of result manipulation, particularly in THC content, and the need for public health officials to address this. Yasha suggests making testing data public to enhance oversight and suggests a national entity to manage this data for better consistency and public safety.